Trends in Clinical and Medical Sciences
Vol. 3 (2023), Issue 1, pp. 62 – 66
ISSN: 2791-0814 (online) 2791-0806 (Print)
DOI: 10.30538/psrp-tmcs2023.0047
ISSN: 2791-0814 (online) 2791-0806 (Print)
DOI: 10.30538/psrp-tmcs2023.0047
Evaluation of C-reactive protein/albumin ratio as an early warning parameter in critical COVID-19 cases
Ebru Aladag\(^1\) and Eyüp Aydogan\(^{1,∗}\)
\(^{1}\) Anesthesiology and Reanimation Department, ALKU Alanya Training and Research Hospital, Figla, 07400 ‘Alanya/Antalya, Türkiye.
Correspondence should be addressed to Eyüp Aydogan at eyup.aydogan@alanya.edu.tr
Copyright © 2023 Ebru Aladag and Eyüp Aydogan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: October 29, 2022 – Accepted: February 28, 2023 – Published: March 31, 2023
Abstract
Introduction: In 2019, a new coronavirus disease spread throughout the world from the city of Wuhan, China. COVID-19 is divided into four groups according to clinical symptoms and disease severity: mild, moderate, severe, and critical. Budgeted rates of CRP and albumin utilization will be used to estimate the incidence of COVID-19 cases. Based on this data, the aim of this study is to evaluate the diagnostic power of the C-reactive protein to albumin ratio in the early differentiation of severe hospitalized cases of COVID-19.
Materials and Methods: During hospitalization, cases will be classified as mild, moderate, severe, and critical according to the WHO interim guidance. The mild and moderate subgroups will be classified as non-severe (group 1), and the severe and critical subgroups will be classified as severe (group 2). Demographic data, morbidity, and mortality rates will be recorded.
Results: The exitus rates and length of hospital stay were significantly higher in group 2.
Conclusions: The C-reactive protein/albumin ratio has predictive value in severe COVID-19 patients who are candidates for ICU admission or endotracheal intubation. However, it is thought that supporting this data with a larger number of patients and multicenter studies would increase the value of the data.
Materials and Methods: During hospitalization, cases will be classified as mild, moderate, severe, and critical according to the WHO interim guidance. The mild and moderate subgroups will be classified as non-severe (group 1), and the severe and critical subgroups will be classified as severe (group 2). Demographic data, morbidity, and mortality rates will be recorded.
Results: The exitus rates and length of hospital stay were significantly higher in group 2.
Conclusions: The C-reactive protein/albumin ratio has predictive value in severe COVID-19 patients who are candidates for ICU admission or endotracheal intubation. However, it is thought that supporting this data with a larger number of patients and multicenter studies would increase the value of the data.
Keywords:
COVID-19; C-reactive protein; Albumin; Disease severity; Hospitalization.